Compare Crispr Therapeutics AG (CRSP) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs PepsiCo, Inc. — how do they compare? Crispr Therapeutics AG trades at $53.43 (market cap $4.88B), while PepsiCo, Inc. trades at $125.77 (market cap $174.89B). The key difference: PepsiCo, Inc. is far larger — about 35.8× Crispr Therapeutics AG's market cap, and PepsiCo, Inc. pays a 4.61% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and PepsiCo, Inc. for 107 Days on average.
| CRSP | PEP | |
|---|---|---|
Market Cap | $4.88B | $174.89B |
Volume | 2,861,747 | 23,968,864 |
Sector | Health | Consumer Staples |
52-Week High | $74.92 | $170.44 |
52-Week Low | $44.34 | $123.64 |
Typical Hold Time | 77 Days | 107 Days |
Enterprise Value | $3.30B | $215.61B |
Dividend Yield | — | 4.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
PepsiCo (PEP) trades at $125.80, up 1.74% today, with a bearish technical signal but strong fundamentals including four consecutive quarterly EPS beats. Revenue grew to $93.93B in 2025, with a net margin of 10.78% and robust cash flow. Analyst consensus is a Buy with a $146.77 price target, though recent news highlights pricing pressures in snacks.
The outlook is mixed: strong profitability and institutional support offer upside, but bearish technicals and consumer pushback on high prices pose near-term risks. Execution on North American turnaround and margin expansion will be critical for sustained growth amid competitive and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
